Biotechnology stocks to buy now
Every day TheStreet Ratings produces a list of the top rated stocks , by industry. The following biotech stocks are rated highest by our value-focused model. This list will be updated as upgrades and downgrades occur.
Why Intrexon CEO R. Kirk Should Not Be Trusted 15 Dumbest College Majors if You Want to Make Money When You Graduate Ex-CEO John Sculley Weighs In on Apple-Tesla Merger Talk Does Amazon Really Have Antitrust Issues, Per Trump's Latest Rant?
Every trading day, Real Money offers a wealth of insight, analysis and strategies for all styles of investing.
The SU10 team uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar. With Top Stocks, Helene Meisler uses short and long-term indicators to pinpoint imminent breakouts in stocks. Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria. Your browser is not supported.
Biotech Stock With 50% Profit Margin Nears Buy Zone | Stock News & Stock Market Analysis - IBD
Please upgrade to one of the following browsers: DJIA 70 27 0. NASDAQ 12 40 0.
2 Biotech Stocks to Buy Right Now - Schaeffer's Investment Research
Bank of America's 17 High-Quality Cash-Rich Stocks for Investors to Consider. If Donald Trump Was President, Here's What Would Happen to the U. Yogi Berra's 14 Great 'Yogi-Isms' to Apply in Life and the Business World.
Chesapeake Energy CHK Stock Soars on Q1 Results, Asset Sales. INVEST WITH CRAMER FREE for 14 Days.
BlueChipPennyStocks - The number one trusted financial newsletter site
Compare All Subscription Services. After 16 years writing about biotech stocks for TheStreet, it's time for this writer to say goodbye and thank you. Goodbye CytRx, Your Game Is Over. Juno Therapeutics Mounts CAR-T Comeback With Strong Lymphoma Study Results. Rivals Kite Pharma and Novartis are still out in front, but updated efficacy and safety data from Juno's JCAR program in patients with aggressive non-Hodgkin's lymphoma are very competitive.
Bluebird, Celgene CAR-T Keeps Multiple Myeloma Patients Relapse Free. This will be the investors' verdict on the results of Roche's APHINITY study of Perjeta in adjuvant breast cancer treatment that were released Monday morning. Missing Patients Cloud View of Incyte's IDO Drug Lung Cancer Study. Incyte's actions are another reminder that biotech companies carefully groom and manage the clinical data they want investors to see, even at important, open medical meetings like ASCO.
Incyte 'IDO' Combination Lung Cancer Results Improve Slightly at ASCO Incyte and Merck are combining two cancer immunotherapy drugs to treat patients with non-small cell lung cancer. Loxo Drug Notches Strikingly High Response Rates in Genetically Defined Tumors.
The Loxo data also represent another advance for precision cancer medicine, in which patients are treated with drugs that target specific tumor mutations, regardless of where the cancer originates. Bullish Puma Investor Talks Neratinb FDA Panel Win, Next Steps and Takeout Potential.
A head-to-head showdown in metastatic breast cancer and the Roche APHINITY data are next key events for Puma. Puma Bio FDA Advisory Panel Live Blog. Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote. The lack of "OMG" bombshells in the FDA's neratinib review are a Monday win for Puma bulls, and the stock is soaring. Amgen Osteoporosis Drug Approval Plan Derailed Over Heart Safety Risk -- Jim Cramer Weighs In.
Amgen's osteoporosis setback will likely be seen as providing a commercial boost to Radius Health, which secured U.
Mixed Outcomes for La Jolla Pharma Shock Drug Fuels Debate Over Sales Potential. LJPC reversed dangerously low blood pressure in patients suffering from a severe form of shock, but the drug did not improve total organ function or reduce mortality.
Incyte Shares Vault After 'IDO' Cancer Immunotherapy Combo Data Revealed. The new Incyte data revealed ahead of the ASCO meeting in June involve combination therapies with Merck and Bristol-Myers Squibb in multiple types of cancer. Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO '17 Meeting.
The drug companies engineering T-cells to recognize and kill cancer, otherwise known as chimeric antigen receptor T-cells, or CAR-Ts, will be busy at the ASCO annual meeting in June. Here's Why Valeant's Stock Is Heading Straight to Zero Biotech Stock Mailbag: CHECK OUT OUR BEST SERVICES FOR INVESTORS ACTION ALERTS PLUS Portfolio Manager Jim Cramer and the AAP Team reveal their investment tactics while giving advanced notice before every trade.
Access to Jim Cramer's daily blog Intraday commentary and news Real-time trading forums. Includes Real Money Kass, Cramer and 15 other Wall Street Pros Intraday commentary and news Actionable investing ideas, including options trading. Model Portfolio Intraday Trade alerts Access to TheStreet Quant Ratings. Unrestricted use of the stock screener Complete access to our ratings database of over 4, stocks Unlimited research reports on your favorite stocks "Top of the Class" list of the best stocks in every sector and sub-industry.
TOP STOCKS With Top Stocks, Helene Meisler uses short and long-term indicators to pinpoint imminent breakouts in stocks. Daily trading ideas and technical analysis Daily market commentary and analysis Technical charts and analysis. DAILY SWING TRADE Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria. Momentum trading Daily swing trade picks Technical charts and analysis Swing trade instruction.
Home Cramer Banking Biotech ETFs Opinion Personal Finance Retail Tech Video. Featured Topics Jim Cramer Mad Money Stock Market Today Dow Jones Today Dividend Stocks Gold Price Silver Prices Copper Prices Oil Prices. Popular Pages Best Stocks Best Stocks to Buy High Dividend Stocks Stock Market Holidays Earnings Calendar Ex Dividend Date ETF Ratings Mutual Fund Ratings Best Online Brokers.
Stay Connected Feedback About Us Write For TheStreet Investor Relations Advertise Reprints Customer Service Employment Privacy Policy Terms of Use Topic Archive Video Sitemap Data Affiliate Press Room. Action Alerts PLUS is a registered trademark of TheStreet, Inc.